Skip to main content
    I

    Ideaya Biosciences Inc (IDYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $30.36
    -1.47 (-4.62%)

    Market Cap: $3.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ideaya Biosciences Inc (IDYA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Ideaya Biosciences (IDYA) to earn -$4.77 per share in the fiscal year ending Dec 31, 2026, on revenue of $42.40M. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.

    RatingAnalystsShare
    Strong Buy318.8%
    Buy1275.0%
    Hold16.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    16

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 193.5%.

    Fiscal year ending Dec 31, 2026
    -$4.77
    EPS consensus, revenue $42.40M
    Fiscal year ending Dec 31, 2027
    -$4.15
    EPS consensus, revenue $124.45M
    Next report
    Feb 15, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.77-$5.05 to -$4.4811$42.40M$25.66M to $75.70M15
    Dec 31, 2027-$4.15-$5.46 to -$2.4713$124.45M$17.70M to $264.86M16

    Quarterly Estimates

    The EPS consensus rises from -$1.25 for the quarter ending Dec 31, 2026 to -$1.24 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.25-$1.42 to -$0.8717$16.56MN/A16
    Mar 31, 2027-$1.24-$1.41 to -$1.046$9.23MN/A8

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202611
    Fiscal year ending Dec 31, 202722

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.61.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.77-$4.59-$4.58-$4.61-$4.61N/A
    Fiscal year ending Dec 31, 2027-$4.15-$4.11-$4.01-$4.10-$4.11N/A
    Quarter ending Mar 31, 2027-$1.24-$1.21-$1.15-$1.19-$1.18N/A

    Frequently Asked Questions About IDYA

    What is the IDYA stock forecast?

    Consensus analyst estimates put Ideaya Biosciences's EPS at -$4.77 for the fiscal year ending Dec 31, 2026, on revenue of $42.40M. The consensus rating from 16 analysts is Buy.

    How do analysts rate IDYA stock?

    Of 16 analysts covering Ideaya Biosciences, 3 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from IDYA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.77, with estimates from -$5.05 to -$4.48 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.15, with estimates from -$5.46 to -$2.47 from 13 analysts.

    What revenue do analysts expect from Ideaya Biosciences next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $42.40M, with estimates from $25.66M to $75.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $124.45M, with estimates from $17.70M to $264.86M.

    How many analysts cover IDYA?

    16 analysts rate Ideaya Biosciences stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.